Supreme Court rejects plea by US pharma firms
- BJP rubbishes Geelani's claim, calls separatist leader's 'Modi emissary talk' as 'false and mischievous'
- Modi's jibe at Mulayam: âBalaatkariyon ke liye Netaji ka mann ekdum mulayam haiâ
- Malaysian Airlines MH370: 4 questions about missing plane answered
- After denying a 'Modi wave', Joshi endorses Modi as India's next PM
- Elections 2014 LIVE: Sonia and Rahul were the primary decision makers while Manmohan was just a facade, says Modi
The Supreme Court on Friday turned down a request by US pharmaceutical firms Sugen and Pharmacia & Upjohn Company for transfer of its case (revocation of a patent for anti-cancer drug Sunitinib) to another patent officer.
Noting that there did not appear to be sufficient grounds for entertaining such a plea when no instance or allegations of bias against the concerned patent officer was on record, a Bench led by Justice KS Radhakrishnan said that it will not be fair to transfer the matter to another Controller of Patents and Designs.
Earlier, senior counsel TR Andhyarujina had contended before the Bench that the dispute should now be heard by a different patent officer since the officer in question has already heard it before.
He said that there was a possibility that the officer would be influenced by her previous order when she had revoked the patent.
The senior counsel added that principles of natural justice also demanded an approval of their request.
The Bench, however, observed that a mere apprehension of this nature was not adequate when there was nothing else on record to substantiate this averment.